UNSPSC 51162723: Guaiacol phosphate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C21H21O7P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56492O1F0U, chemically known as phenol, 2-methoxy-, phosphate (3:1), but more generally known as guaiacol phosphate, which bears US NIH Compound Identifier 68420. European Medicines Agency schedules guaiacol phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG.

Most nations, for tariff purposes, schedule guaiacol phosphate under HS 29095000. SMILES: COC1CCCCC1OP(=O)(OC2CCCCC2OC)OC3CCCCC3OC.

UNSPSC 51162723 Guaiacol phosphate is a Commodity code that in recent state and local procurement activity covers parenteral pharmaceutical products and related healthcare supplies—specifically intravenous solutions, parenteral nutrition preparations, and controlled substances delivered to correctional and public health facilities. The Washington State Department of Corrections and Seminole County, Florida have posted opportunities under this code for medical-grade pharmaceutical procurement to support incarcerated populations and community health initiatives. Issuing bodies soliciting under this code include state corrections departments and county health authorities; both are repeat buyers managing healthcare delivery to specific institutional populations. The work involves not just product supply but also preparation services, delivery logistics with strict time windows, and documented clinical monitoring capabilities—vendors must demonstrate experience with IV solution preparation, patient lab result monitoring, and the ability to adjust pharmaceutical formulations to individual patient needs.

Activity centers on Washington State and Florida based on recent postings. The Washington State Department of Corrections issued RFQ RFQQK13020 (due October 7, 2026) for parenteral products, services, and equipment to supply eight correctional facilities across three regions, with bids due October 7, 2026 and a pre-bid conference on September 23, 2026; the initial contract term runs November 26, 2026 through June 30, 2030, with DOC retaining discretionary extension rights, and the agency anticipates selecting multiple contractors with up to three bidders per region. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building. Both opportunities require compliance with state small and diverse business utilization goals, drug-free workplace certification, E-Verify compliance, and specified insurance coverage including commercial general liability and professional liability.